Biogened Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Biogened has been growing earnings at an average annual rate of 31.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 19.2% per year. Biogened's return on equity is 13.7%, and it has net margins of 5.1%.

Belangrijke informatie

31.8%

Groei van de winst

32.5%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie29.4%
Inkomstengroei19.2%
Rendement op eigen vermogen13.7%
Nettomarge5.1%
Volgende winstupdate14 Nov 2024

Recente prestatie-updates uit het verleden

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Recent updates

A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Aug 28
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

May 23
Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

May 09
Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Is Biogened (WSE:BGD) A Risky Investment?

Feb 01
Is Biogened (WSE:BGD) A Risky Investment?

Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

Feb 01
Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Jun 30
We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Oct 08
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

Mar 25
Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Dec 09
These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Jul 29
Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Apr 30
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jan 24
Is Biogened (WSE:BGD) A Risky Investment?

Opbrengsten en kosten

Hoe Biogened geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

WSE:BGD Opbrengsten, kosten en inkomsten (PLN Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 241065610
31 Mar 241004580
31 Dec 23965550
30 Sep 23924470
30 Jun 23904460
31 Mar 23854450
31 Dec 22803420
30 Sep 22774410
30 Jun 22724360
31 Mar 22703360
31 Dec 21652350
30 Sep 21572330
30 Jun 21542330
31 Mar 21501300
31 Dec 20481300
30 Sep 20492290
30 Jun 20481290
31 Mar 20481290
31 Dec 19471280
30 Sep 19451280
30 Jun 19441270
31 Mar 19411260
31 Dec 18401260
30 Sep 18391240
30 Jun 18391240
31 Mar 18361220
31 Dec 17341210
30 Sep 17301190
30 Jun 17311200
31 Mar 17291190
31 Dec 16291190
30 Sep 16322210
30 Jun 16312200
31 Mar 16313190
31 Dec 15303180
30 Sep 15302180
30 Jun 15261150
31 Mar 15241140
31 Dec 14231130
30 Sep 14201120
30 Jun 14211120
31 Mar 14221130
31 Dec 13222120

Kwaliteitswinsten: BGD has high quality earnings.

Groeiende winstmarge: BGD's current net profit margins (5.1%) are higher than last year (3.9%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: BGD's earnings have grown significantly by 31.8% per year over the past 5 years.

Versnelling van de groei: BGD's earnings growth over the past year (53%) exceeds its 5-year average (31.8% per year).

Winst versus industrie: BGD earnings growth over the past year (53%) exceeded the Pharmaceuticals industry 4.5%.


Rendement op eigen vermogen

Hoge ROE: BGD's Return on Equity (13.7%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden